- Home
- CCB vs ANAB Comparison
CCB vs ANAB Comparison
Compare CCB & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCB
- ANAB
- Stock Information
- Founded
- CCB 1997
- ANAB 2005
- Country
- CCB United States
- ANAB United States
- Employees
- CCB N/A
- ANAB N/A
- Industry
- CCB Major Banks
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- CCB Finance
- ANAB Health Care
- Exchange
- CCB Nasdaq
- ANAB Nasdaq
- Market Cap
- CCB 811.4M
- ANAB 759.5M
- IPO Year
- CCB 2018
- ANAB 2017
- Fundamental
- Price
- CCB $79.54
- ANAB $15.43
- Analyst Decision
- CCB Strong Buy
- ANAB Buy
- Analyst Count
- CCB 2
- ANAB 11
- Target Price
- CCB $84.50
- ANAB $46.00
- AVG Volume (30 Days)
- CCB 116.7K
- ANAB 741.9K
- Earning Date
- CCB 01-28-2025
- ANAB 11-05-2024
- Dividend Yield
- CCB N/A
- ANAB N/A
- EPS Growth
- CCB N/A
- ANAB N/A
- EPS
- CCB 2.98
- ANAB N/A
- Revenue
- CCB $284,123,000.00
- ANAB $57,172,000.00
- Revenue This Year
- CCB N/A
- ANAB $233.68
- Revenue Next Year
- CCB $27.25
- ANAB N/A
- P/E Ratio
- CCB $28.31
- ANAB N/A
- Revenue Growth
- CCB 8.86
- ANAB 282.17
- 52 Week Low
- CCB $35.67
- ANAB $14.20
- 52 Week High
- CCB $86.27
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- CCB 58.10
- ANAB 34.47
- Support Level
- CCB $73.80
- ANAB $15.11
- Resistance Level
- CCB $86.27
- ANAB $17.34
- Average True Range (ATR)
- CCB 2.80
- ANAB 1.95
- MACD
- CCB 0.09
- ANAB -0.54
- Stochastic Oscillator
- CCB 46.03
- ANAB 16.82
About CCB Coastal Financial Corporation
Coastal Financial Corp is a financial service provider. The company provides banking products and services to consumers and small to medium-sized businesses. Its business is conducted through three reportable segments: The community bank, CCBX, and treasury & administration. The primary focus of the community bank is on providing a wide range of banking products and services to consumers and small to medium-sized businesses in the broader Puget Sound region in the state of Washington and through the Internet and mobile banking applications.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).